Search Results for "ATTRv"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Givosiran: Hemin Use
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
Transition between Patisiran and Vutrisiran
Standard response letter on transitioning between patisiran and vutrisiran therapy.
Standard response letter on transitioning between patisiran and vutrisiran therapy.
Patisiran: APOLLO-B Study
Standard response letter on patisiran and the APOLLO-B study, a study evaluating the efficacy and safety of patisiran in patients with ATTR with cardiomyopathy, including both hATTR and wtATTR.
Standard response letter on patisiran and the APOLLO-B study, a study evaluating the efficacy and safety of patisiran in patients with ATTR with cardiomyopathy, including both hATTR and wtATTR.
Vutrisiran: Use in Patients with Renal Impairment
Standard response letter on vutrisiran and use in patients with renal impairment.
Standard response letter on vutrisiran and use in patients with renal impairment.
Patisiran: APOLLO Study Results
Standard response letter on patisiran and the APOLLO study, a phase 3 study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Standard response letter on patisiran and the APOLLO study, a phase 3 study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Patisiran: APOLLO-B OLE Study
Standard response letter on the APOLLO-B OLE study of patisiran.
Standard response letter on the APOLLO-B OLE study of patisiran.
Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Vutrisiran: Randomized Treatment Extension Period of the HELIOS-A Study
Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.
Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.
Vutrisiran: Pain in Extremity
Standard response letter on vutrisiran and the adverse event of pain in extremity.
Standard response letter on vutrisiran and the adverse event of pain in extremity.
Vutrisiran: HELIOS-B
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
